What is the price-to-earnings ratio of Ipsen?
The price-earnings ratio of Ipsen is currently 2.91.
Ipsen P/S 2024
Ipsen P/S
2.91
Ticker
IPN.PA
ISIN
FR0010259150
WKN
A0ESMG
As of Sep 17, 2024, Ipsen's P/S ratio stood at 2.91, a 3.93% change from the 2.8 P/S ratio recorded in the previous year.
The Ipsen P/S history
Ipsen Aktienanalyse
What does Ipsen do?
Ipsen SA is a French biopharmaceutical company specialized in the development of drugs for the treatment of cancer, neurological disorders, and endocrine disorders. It was founded in 1929 by a pharmacist named Henri Beaufour and is headquartered in Paris. The history of Ipsen began with the production of extraction products from snake venom for the manufacturing of serum against tetanus and diphtheria. In the 1960s, the company started to focus on the production of hormones and peptides, with a focus on endocrine disorders. In the 1990s, Ipsen expanded its product portfolio to include oncology and neurological disorders. Ipsen's business model focuses on research and development of new drugs, as well as marketing of already established drugs in selected markets worldwide. The company employs around 5,700 employees and operates in more than 115 countries. Ipsen has two main business segments: specialty drugs and consumer healthcare. The specialty drugs segment focuses on the development and marketing of innovative therapies in the areas of oncology, endocrinology, and neuroscience. Ipsen's most well-known products include Somatuline, a drug for the treatment of acromegaly, and Decapeptyl, a drug for the treatment of prostate cancer and endometriosis. In the consumer healthcare segment, Ipsen is mainly specialized in the production of drugs for the treatment of gastrointestinal disorders and cold and flu symptoms. Some well-known brands include Smecta, a drug for diarrhea, and Nurofen, a pain reliever. Ipsen also has a strong presence in the field of aesthetic medicine, where the company operates a subsidiary called Ipsen Aesthetic. This subsidiary develops and markets products for the treatment of wrinkles and other signs of aging on the skin. Well-known brands of Ipsen Aesthetic include Dysport, a botulinum toxin product for the treatment of wrinkles, and the filler Restylane. Overall, Ipsen has established itself as a leading biopharmaceutical company focused on the development and marketing of products in specialized therapy areas. The company has a strong pipeline of new products in development and remains an important player in the pharmaceutical industry due to its strong scientific expertise and global presence. Ipsen ist eines der beliebtesten Unternehmen auf Eulerpool.com.P/S Details
Decoding Ipsen's P/S Ratio
Ipsen's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.
Year-to-Year Comparison
Comparing Ipsen's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.
Impact on Investments
The P/S ratio is instrumental for investors evaluating Ipsen's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.
Interpreting P/S Ratio Fluctuations
Variations in Ipsen’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.
Frequently Asked Questions about Ipsen stock
How has the price-earnings ratio of Ipsen changed compared to last year?
The price-to-earnings ratio of Ipsen has increased by 3.93% increased compared to last year.
What consequences does a high price-earnings ratio have for investors?
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
What does a low price-earnings ratio mean?
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Is the price-earnings ratio of Ipsen high compared to other companies?
Yes, the price-to-earnings ratio of Ipsen is high compared to other companies.
How does an increase in the price-earnings ratio of Ipsen affect the company?
An increase in the price-earnings ratio of Ipsen would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
How does a reduction in the price-to-earnings ratio of Ipsen affect the company?
A decrease in the price-earnings ratio of Ipsen would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
What are some factors that influence the price-earnings ratio of Ipsen?
Some factors that influence the price-earnings ratio of Ipsen are the company's growth, financial position, industry development, and the overall economic situation.
How much dividend does Ipsen pay?
Over the past 12 months, Ipsen paid a dividend of 1.2 EUR . This corresponds to a dividend yield of about 1.09 %. For the coming 12 months, Ipsen is expected to pay a dividend of 1.4 EUR.
What is the dividend yield of Ipsen?
The current dividend yield of Ipsen is 1.09 %.
When does Ipsen pay dividends?
Ipsen pays a quarterly dividend. This is distributed in the months of June, June, July, June.
How secure is the dividend of Ipsen?
Ipsen paid dividends every year for the past 24 years.
What is the dividend of Ipsen?
For the upcoming 12 months, dividends amounting to 1.4 EUR are expected. This corresponds to a dividend yield of 1.27 %.
In which sector is Ipsen located?
Ipsen is assigned to the 'Health' sector.
Wann musste ich die Aktien von Ipsen kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Ipsen from 6/3/2024 amounting to 1.2 EUR, you needed to have the stock in your portfolio before the ex-date on 5/30/2024.
When did Ipsen pay the last dividend?
The last dividend was paid out on 6/3/2024.
What was the dividend of Ipsen in the year 2023?
In the year 2023, Ipsen distributed 1.2 EUR as dividends.
In which currency does Ipsen pay out the dividend?
The dividends of Ipsen are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Ipsen stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von Ipsen
Our stock analysis for Ipsen Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Ipsen Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
